Icatibant
- Generic Name
- Icatibant
- Brand Names
- Firazyr, Sajazir, Icatibant Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C59H89N19O13S
- CAS Number
- 130308-48-4
- Unique Ingredient Identifier
- 7PG89G35Q7
- Background
Icatibant (Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant cur...
- Indication
Approved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections.
- Associated Conditions
- ACE Inhibitor-associated Angioedema, Hereditary angioedema breakthrough attack
- Associated Therapies
- -
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT01457430
- Locations
- 🇺🇸
San Diego Veterans Affairs Medical Center, La Jolla, California, United States
🇺🇸UCLA - David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Penn State University, Hershey, Pennsylvania, United States
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 32
- Registration Number
- NCT01386658
- Locations
- 🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia
🇺🇸Penn State University, Hershey, Pennsylvania, United States
🇺🇸University of South Florida, Tampa, Florida, United States
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 151
- Registration Number
- NCT00997204
- Locations
- 🇦🇷
Hospital Britanico Unidad de Alergia, Buenos Aires, Argentina
🇦🇹Universitätsklinik für Dermatologie und Venerologie, Graz, Austria
🇮🇱Tel Aviv Sourasky Medical Center - Allergy Unit, Tel Aviv, Israel
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 98
- Registration Number
- NCT00912093
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh (of UMPC), Pittsburgh, Pennsylvania, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Speciality Medical Clinic & Research Center, Stanford, California, United States
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
- Conditions
- Interventions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 85
- Registration Number
- NCT00500656
- Locations
- 🇮🇹
Università degli Studi di Milano, Dipartimento di Medicina Interna, Milano, Italy
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
- First Posted Date
- 2004-11-29
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 84
- Registration Number
- NCT00097695
- Locations
- 🇺🇸
Georgetown University Hospital, Lombardi Cancer Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.